| SELL | 3.880 | David Chapman | Not a fan of biotech stocks. Difficult to read with all the little points of approval or non-approval. With the big spike, don't buy. | 2004-12-03 | |
| TOP PICK | 67.580 | Alison Deans | The entire energy sector is an interesting play. There has been a shrinkage of capacity in the last several years. | 2004-04-23 | |
| DON'T BUY | 1.850 | Ross Healy | Outlook is anybody's guess. No earnings. | 2003-01-16 | |
| DON'T BUY | 6.280 | Ray Steele | Will take a while. Prefers Isotechnica, | 2002-01-16 | |
| BUY on WEAKNESS | 6.750 | Brian Acker, CA | RISKY. No earnings. Treat as a trading stock between $5 and $7. | 2001-12-28 | |
| BUY | 7.000 | Peter Brieger | Good long term investment, but prefers MDS. | 2001-11-14 | |
| DON'T BUY | 6.000 | Glenn Paradis, BA, CFA | Great product, but company has had problems. | 2001-10-31 | |
| DON'T BUY | 6.300 | Brian Acker, CA | Biotechs out of favour. Has broken $6.40. Next level is $3.90. | 2001-09-19 | |
| WAIT | 12.640 | John Zechner | Taking a long time to get to market. | 2001-05-25 | |
| DON'T BUY | 11.080 | John Zechner | Doesn't have top line growth. Some products in 3rd phase. Speculative. | 2001-05-18 | |
| BUY on WEAKNESS | 12.960 | Glenn Paradis, BA, CFA | In phase 3 and has partnered with Merk. | 2001-05-04 | |
| BUY | 10.380 | David Baskin | Smart mngmnt. Good sector. Big litigation risk re: patents/class action suits in pharmaceuticals. | 2001-04-09 | |
| BUY | 12.400 | Glenn Paradis, BA, CFA | Good company. Drugs in 3rd phase. Short term should do well. Getting a new partner | 2001-02-01 | |
| BUY on WEAKNESS | 12.850 | Steven Misener | A very active/volatile stock. Lots of press | 2001-01-23 | |
| DON'T BUY | 13.000 | Fred Ketchen | Difficult to select which bio company but prefers BioChem or a fund | 2000-11-21 | |
| DON'T BUY | 15.000 | Ross Healy | No earnings Speculative play Loss because of research costs | 2000-11-08 | |
| DON'T BUY | 14.000 | Robert Floyd | News driven. Have to have good balance sheets | 2000-11-01 | |
| STRONG BUY | 14.000 | Glenn Paradis, BA, CFA | Undervalued. Market waiting for a partner & test results. Should be there by year end | 2000-10-13 | |
Experts that have talked about Biomira
Rss Top Picks Feed
